Dynavax Files Investor Presentation with Shareholders

Published: 2025-05-12 03:41:00 ET DVAX

Published on 05/12/2025 at 03:41, updated on 05/12/2025 at 09:51

On May 12, 2025, Dynavax Technologies Corporation announced that it has filed an investor presentation with shareholders, stating that the Company has delivered a 203% total return to stockholders over the last 5 years, significantly outperforming its peers and industry indices, and its hepatitis B vaccine, has achieved market leadership with substantial revenue growth. In addition, the Company stated that it has generated over $950 million in net product revenue during the pandemic and has executed a strategic capital allocation plan, including a significant share repurchase program. Further, the Company?s board stated that it has undergone extensive refreshment, with directors bringing valuable expertise in strategic leadership, vaccine development, biotechnology, and finance, and argues that Deep Track's plan to monetize HEPLISAV-B® for short-term gains is flawed and risks long-term growth, Deep Track's nominees lack the necessary expertise to drive the company's future success.

The Company stated that its board of directors are committed to acting in the best interests of all stockholders and unanimously recommends that stockholders vote for its board nominees Brent MacGregor, Scott Myers, Lauren Silvernail and Elaine Sun, at the annual meeting of shareholders scheduled to be held on June 12, 2025.